Spontaneous Coronary Artery Dissection - AntipLatelet Therapy Intensity in Guided coNservative Management (SCAD-ALIGN) Trial

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 3518 participants.

Also called NCT07683923

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 3,518 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07683923
  • EU CT 2025-523985-26-00
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Canada, Germany, Netherlands, Sweden, United Kingdom (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07683923. Randomized; single masking; primary purpose treatment. Start 2027-03-01 (anticipated); primary completion 2033-02-28 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Spontaneous Coronary Artery Dissection - AntipLatelet Therapy Intensity in Guided coNservative Management (SCAD-ALIGN) Trial
Acronym
SCAD-ALIGN
Condition
SCAD
Condition
ACS (Acute Coronary Syndrome)
Intervention (Drug)
Acetylsalicylic acid ASA
Intervention (Drug)
ASA plus Clopidogrel
Lead sponsor
Universitätsklinikum Hamburg-Eppendorf (class: other)
Collaborator
National Institute for Health Research Leicester Biomedical Research Centre, Leicester, UK (class: other)
Collaborator
Gesellschaft für Therapieforschung mbH (class: industry)
Collaborator
Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK) (class: other)
Collaborator
Davos Life Science Pte Ltd (class: industry)

Record details

Record id
cardio:ct-nct07683923
Content hash
6c74cef06e5725310b4165d9ed2934235ea444b3c8220e4cb597ebdbf6f68958